We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Provisional approval
Therapeutic area
Oncology